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Abstract
Objectives—Patients ≥65 years old (“older”) are often not included in randomized clinical trials
(RCT), but when they are, care in an RCT might improve quality of life (QoL). We conducted a
prospective comparison of QoL among older women receiving standard chemotherapy from the
same cooperative group physicians in an RCT vs. an observational study (“off-trial”).
Methods—Older women with invasive, non-metastatic breast cancer (n = 150 RCT; 530 off-
trial) were included. Linear mixed-effects models tested associations between chemotherapy on-
vs. off-trial and changes in EORTC (European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire) QoL scores over 24 months, controlling for pre-treatment
QoL, age, education, tumor factors, comorbidity, and other covariates.
Results—Anthracycline regimens were used by 58% of women treated on-trial vs. 54% of those
treated off-trial. Women in the RCT reported an adjusted mean increase of 13.7 points (95% CI
10.2, 17.1) in global QoL at 24 months (vs. mid-treatment), while women treated off-trial had only
an adjusted improvement of 7.0 points (95% CI 3.5, 10.4; p = .007 for difference in mean
changes). Women in the RCT had significantly greater improvement in emotional function than
those treated off-trial, controlling for baseline; they also had greater reductions in therapy side
effects and fatigue at 24 months than women off-trial, controlling for covariates.
Conclusion—There may be different QoL trajectories for older women undergoing breast
cancer chemotherapy on- vs. off-trial. If confirmed, the results suggest that the extra monitoring
and communication within an RCT could provide the infrastructure for interventions to address
symptoms and improve QoL for the growing older cancer population.
Keywords
Older patients; Breast cancer; Chemotherapy; Quality of Life; Randomized clinical trials;
Observational studies
1. Introduction
Women 65 years and older, hereafter older, constitute almost half of all new invasive breast
cancer cases and account for two-thirds of the deaths each year from this disease.1 With the
graying of America, the absolute number of older breast cancer patients and survivors will
increase substantially over the coming decades. Despite this demographic imperative, we
know little about chemotherapy efficacy and post-chemotherapy quality of life (QoL) in
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older women since this group has been under-represented in randomized clinical trials
(RCTs).2
Kemeny and colleagues reported that older women would enroll in a chemotherapy clinical
trial if it was offered to them.3 Further, there are now trials designed specifically for the
older cancer patients.4 Increasing the number of older women receiving chemotherapy
within RCTs could increase the knowledge base about treatment efficacy and might have
additional benefits for this group. For instance, the added attention and required monitoring
in trial settings could potentially result in better outcomes for older women than those
receiving comparable therapy delivered outside of trials.
We designed a prospective comparison of an RCT evaluating standard chemotherapy and
oral capecitabine4 and an observational study of standard chemotherapy.5 The protocols for
these studies had nearly identical inclusion criteria, were conducted in the same cooperative
group sites by the same groups of providers and included a core of shared instruments. In
this paper, we use data from women in the standard chemotherapy arm of the RCT and
women receiving chemotherapy in the observational study to compare 24-month post-
treatment QoL outcomes for these on- and off-RCT groups. We hypothesized that the
women treated on the trial would have better QoL than women in the observational study
even after considering baseline QoL, socio-demographic, clinical, and care setting
differences between the groups. If there is improved QoL for women treated in clinical
trials, this might suggest that there could be benefits from the enhanced surveillance for
toxicity, attention to side effects and/or other interactions with providers associated with the
quality and intensity of care delivered in RCTs. If confirmed, this information could advance
knowledge to improve care of the growing population of older cancer patients.
2. Methods
The studies were conducted at 75 Cancer and Leukemia Group B (CALGB) sites (now part
of the Alliance for Clinical Trials in Oncology). The protocols met HIPAA standards and
were approved by the CALGB, the National Cancer Institute and all local IRBs. The studies
and settings have been described in detail elsewhere4,5 and are summarized below. Protocol
#49907 was an RCT comparing oral capecitabine and standard chemotherapy in older
women and included an embedded QoL study.6 The parallel observational study (protocol
#369901) evaluated factors associated with older women’s decisions to receive
chemotherapy and assessed QoL.5,7 Site clinical research associates obtained written
consent from participants in both studies.
2.1 Setting and Population
Eligible participants in both protocols were 65 years or older, with newly diagnosed,
primary histologically confirmed invasive non-metastatic breast cancer tumors stage T1–3,
N0–3, M0. All performance status categories were eligible for the observational study. In
the RCT women were required to have a performance status of 0–2 (fully active, or some
impairments but can work, and ambulatory and can do self-care, but can’t work,
respectively) vs. 3–5 (confined, totally disabled, or dead, respectively) as measured by the
treating physicians and expected survival greater than five years; performance status was not
a criteria for the observational study and was not measured. For both studies, women with a
score of ≥11 on the Blessed Orientation-Memory-Concentration test8 were excluded as
having potential cognitive impairment that might interfere with ability to consent and
complete study procedures.
The RCT enrolled women in the QoL component from September 2001 to December 2006;
follow-up was completed by 2008. The trial required six survey assessments over the course
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of 24 months and visits for RCT-specific laboratory assessments. The observational study
enrolled women from December 2004 to April 2011. The observational study required four
survey assessments during the first 24 months and no study-specific laboratory assessments.
We considered year of enrollment in our statistical analyses.
For the analysis of QoL outcomes, the target population included women from the RCT on
the standard chemotherapy arm and women from the observational study who received the
same standard chemotherapies (Fig. 1). The mid-treatment assessment was the first time-
point assessed in the observational study. Therefore, for this analysis we included the 150
and 530 women who completed mid-treatment interviews in the RCT and observational
study, respectively (Fig. 1). Note that none of the women in the observational study were
participants in other treatment trials. Women in the target population for the observational
study tended to be older than those who were included in the RCT for the QoL analysis.
2.2. Data Collection
Clinical research associates (CRAs) ascertained patients, confirmed eligibility, approached
physicians for permission to contact patients, and obtained consent. Patient registration was
managed by the CALGB Statistical Center. Patient interviews were completed on the
telephone in a similar manner and at comparable time points (mid-treatment and 12 and 24
months) by trained centralized staff for both protocols. Initial interviews lasted 45 min and
follow-up interviews were about 20 min in both studies. Medical records were abstracted by
CRAs for tumor and treatment data.
2.3. Measures
Type of study was defined by the respective protocol enrollment. This variable is the key
variable predicting QoL outcomes. QoL was measured in both protocols at mid-treatment,
12 and 24 months using the EORTC QLQ-C30 (European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire).9 Mid-treatment was on average 3–5
months post-diagnosis in both groups. The EORTC has 30 items from which we evaluated
the following subscales: global health status, physical functioning, emotional functioning,
cognitive functioning, fatigue, and social functioning. Higher scores on global QoL and the
functioning scales indicate better QoL/ function; higher scores on the fatigue scale indicate
greater fatigue. We also used the EORTC BR23 (Breast Cancer Module) to measure body
image (higher score indicates better image), sexual functioning (higher score indicates better
function), and systemic therapy side effects (higher score indicates more problems with side
effects).10 The reliability of these scales, as evaluated with Cronbach’s alphas, ranged from
0.60 to 0.89 across the entire sample and was similar across study type (0.63–0.92 for the
RCT and 0.60–0.89 for the observational study; the lowest range of reliability was seen for
the emotional and social function scales).
Pre-treatment baseline EORTC-QLQ-C30 was used to control for QoL outcomes in the RCT
group. Since the EORTC-QLQ-C30 was not available at baseline (pre-treatment) for the
observational study, we used available SF-12 (the 12-Item Short Form Health Survey)
measures that were commensurate with corresponding EORTC-QLQ-C30 subscales to
control for baseline QoL. For instance, for the EORTC physical functioning scale, we used
the SF-12 physical components summary score (PCS) for the observational study
participants. Similarly for EORTC emotional and social functioning subscales, we used the
SF-12 mental components summary score (MCS); and for the EORTC fatigue symptoms we
used the SF-12 item: “How much of the time during the past 4 weeks, did you have a lot of
energy?”
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Clinical covariates of QoL outcomes included tumor size, nodal status, ER (estrogen
receptor) status, type of surgery (breast conserving vs. mastectomy), and number of
comorbidities using the OARS (Older Americans Resources and Services) Multidimensional
Functional Assessment 14-item scale.12 Setting of care was measured based on type of site
(National Cancer Institute designated cancer center vs. other). We did not have data on
hormonal therapy, radiation use, or dose intensity in both studies, so could not include these
variables in analysis. To control for the effects of social support on QoL, we controlled for
emotional/informational support (Cronbach’s alpha = .93) and tangible support (Cronbach’s
alpha = .94) using sub-scales of the Medical Outcomes Study (MOS) social support
instrument.11 Finally, we examined several variables as potential correlates of being treated
in the RCT vs. the observational study, including age at enrollment, self-reported race/
ethnicity (categorized as White and non-White), education (< high school or ≥high school),
and marital status (married vs. single, widowed, divorced, or separated).
2.4. Statistical Analysis
We examined univariate associations between type of study (RTC vs. off-trial observational
study) and covariates using chi-square tests, the Cochran–Armitage trend test, and t-tests.
We report unadjusted- and adjusted-means for QoL scores and 95% confidence intervals
separately for the RCT and the observational study. We used linear mixed-effects modeling
to compare changes in adjusted mean QoL scores from mid-treatment to 24 months for
women on the RCT vs. the observational study based on all available data. We estimated
corresponding contrasts to assess differences in average QoL score changes from mid-
treatment to 24 months, controlling for available baseline pre-treatment QoL measures and
other covariates. The baseline QoL measures (EORTC and SF-12) were standardized as z-
scores for both RCT and observational study participants to enhance their comparability.
We retained age, education, tumor size, nodes, surgery, comorbidity, social support, and site
in the models to capture clinically relevant factors and/or variables that could affect
selection into each study; year of enrollment was not significant and was not included in
final models. We also performed similar analyses using propensity score matching methods
(data not shown).13 Since results were consistent across all approaches, we present the
results of the linear mixed-effect models for unmatched data. Analyses were performed
using SAS 9.2 and the MatchIt package14 from R version 2.13.2.
3. Results
The response and follow-up rates for the women receiving chemotherapy on- vs. off-trial are
shown in Fig. 1. Anthracycline-based regimens were used by 58% of the women in the RCT
and 54% of those in the observational study; the remainder used CMF-based treatments. The
average age of women receiving chemotherapy in these two studies was 71 years (SD 5,
range of 65–90 years) (Table 1). Several variables were associated with enrollment in the
RCT vs. the observational study and were used to control for differences in QoL outcomes
in subsequent analyses (Table 1). For instance, women in the RCT had higher educational
levels than women receiving chemotherapy off-trial (84% vs. 54% high school or greater, p
< .001). Of note, women with less tangible support were also more likely to enroll in the
RCT, although the absolute average difference was only 5 points on a 100-point scale (p = .
008). Women in the trial also had a greater proportion of larger and/or node positive cancers
than those in the observational study.
The trajectories of adjusted QoL over the 24 months after treatment varied between the
women who received standard chemotherapy in the RCT and those in the observational
study treated with chemotherapy (Fig. 2 and Table 2). Women in the RCT improved to a
greater extent relative to their mid-treatment scores than women in the observational study,
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after controlling for baseline QoL, age, education, number of comorbidities, clinical factors
and other covariates. For instance, while women in both groups showed what appear to be
the beginnings of declines in physical functioning, women in the RCT maintained scores
well above their mid-treatment levels (a positive change of 3.3 points) (95% CI −0.5, 7.2),
while those in the observational study declined to slightly below their mid-treatment level (a
change of −1.9 points) (95% CI −4.4, 0.5) (p = .024 for the difference) in the 24-month
period, controlling for baseline physical function, age, education, number of comorbidities
and other covariates (Table 3). A similar pattern and magnitude of difference was seen for
all other QoL sub-scales except for sexual and cognitive functioning, where there were
smaller differences that did not reach statistical significance.
Women receiving their chemotherapy in the RCT also had significantly greater decreases in
treatment-related side effects at 24-months compared to mid-treatment than women in the
observational study after adjustment for covariates (−21.1 [95% CI−23.7, −18.6] vs.−8.0
[95% CI−9.6, −6.3], p < .001 for difference in the mean changes, where a negative sign
indicates fewer side effects). In addition, women in the RCT reported less fatigue over time
than women in the observational study, controlling for baseline, and pre-treatment fatigue
(Table 3).
4. Discussion
This is the first study that we are aware of to conduct a planned comparison of the quality of
life of older women receiving chemotherapy in an RCT vs. an observational study in the
same settings and cared for by the same groups of providers. We found that women who
enrolled in the trial had higher educational levels but somewhat lower tangible social
support than women who received their chemotherapy in the observational study. After
controlling for these and other measured factors including available baseline pre-treatment
QoL information, it appears that older women treated in the RCT may have had greater
improvements in QoL across almost all domains in the first 24-months post-treatment than
women who received similar regimens in the observational study. Women treated in the
RCT also appear to have had more improvements in post-treatment symptoms and fatigue
than women in the observational study.
The finding that RCT participants had a higher educational level than those in the
observational study is not surprising and suggests that recruitment and RCT consent
materials for older patients may need to consider literacy.15,16 While the absolute difference
in tangible support between the groups was only 5 points, the result that women with lower
tangible social support were significantly more likely to enroll in the trial than the
observational study is intriguing. It is possible that women with low support recognized that
the RCT structure could provide resources to facilitate their receipt of chemotherapy. If
corroborated, this could be a potential leverage point for increasing participation of older
women in clinical trials.
The finding that QoL improved in both groups over the first 12 months post-treatment is
similar to the trajectory seen in younger breast cancer patients.17 However, in contrast to
younger patients, our older patients seemed to experience some declines in QoL from 12 to
24 months post-treatment. While not statistically significant, if this is confirmed, it might
suggest that age-related declines may begin to overshadow initial improvements after
therapy. Alternatively, the older age group may be experiencing decrements in QoL related
to late- or delayed-effects of treatment based on interactions of chemotherapy and comorbid
conditions.17 These will be important areas for further research and examination of trends
over longer periods of time.
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We found that for almost all domains of QoL, including global QoL, physical, emotional
and social function, fatigue, body image and side effects, chemotherapy-treated older breast
cancer patients in the RCT had greater improvements by 24 months than those in the
observational study, even after considering pre-treatment QoL and their lower mid-treatment
levels. Moreover, the improvements observed 24 months post-chemotherapy for the women
in the RCT would be considered clinically relevant and in the “medium range” based on a
change of approximately 10 points on the EORTC.18–20 This magnitude was seen for global
QoL and several sub-domains. The differences for cognitive functioning were not
statistically significant, but this sub-scale has been reported to have a much narrower range
within which to detect meaningful differences.20 Also, patients in both studies were pre-
screened for cognitive deficits in determining eligibility, limiting heterogeneity in cognitive
functioning and ability to detect group differences.
Since prior assessments of meaningful differences on the EORTC have been conducted
among patients who were almost all under age 65,18–20 it is possible that smaller changes
might translate into important differences in ability of older women to maintain independent
living and function, since older women already have more limitations prior to cancer than
younger women.21,22 Overall, while our results will need to be confirmed, the differences in
adjusted mean score changes over time for the RCT vs. the observational study suggest that
the women in the RCT may have experienced clinically meaningfully better QoL outcomes
than women receiving the same therapies outside of a trial setting and enrolled in an
observational study.
There are several credible explanations for the significantly better QoL changes reported by
women who received standard therapy in a trial compared to their counterparts who received
the same therapy in the same sites by the same groups of providers in the observational
study.23 First, it is possible that the monitoring required in the trial detected medical
conditions that could be treated, improving QoL. Next, the added monitoring by RCT staff
could have resulted in better symptom management than occurred in routine practice.
Alternatively, the added attention and intensity of monitoring in the RCT may have
improved access to the treatment team, enhanced patient–physician communication and
provided a greater sense of patient well-being. Another alternative explanation is that while
both groups had comparable rates of chemotherapy regimens, the RCT group may have
received treatment that was more adherent to guidelines (e.g., more intensive doses, greater
supportive care to complete planned cycles) than the observational group, and thus had
lower mid-treatment QoL values as seen in the RCT vs. the observational group, after
considering stage differences. The improvements over time for the RCT group could then
represent regression to the mean, or the fact that trial monitoring was sufficient to counter
any initial deleterious effects of more intensive trial-based treatment. Since we do not have
data to determine which, if any, of these factors mediate the observed differences in QoL
changes between the trial and off-trial groups, this will be an important area for future
research if our results are confirmed.
While we cannot rule out unmeasured baseline differences between the two study groups,
the studies were designed in parallel for this planned comparison with comparable eligibility
criteria and the outcome differences were robust after controlling for the variables that are
traditionally related to both selection biases and QoL outcomes, such as pre-treatment QoL,
age, education, and comorbidity. The results for the 4 scales where we had pre-treatment
QoL were virtually unchanged whether they were adjusted or unadjusted for baseline pre-
treatment QoL (not shown), suggesting that pre-treatment differences in the groups were
unlikely to account for the differences in 24-month outcomes observed. While our
conclusion has face validity, prior studies comparing outcomes in RCT vs. non-RCT groups
have been inconsistent.23,24 Thus, our results will need to be confirmed using a clinical trial
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design, where receipt of treatment on- vs. off-trial is randomly allocated to eliminate any
unmeasured confounding variables associated with imbalances in the groups and study
selection.23 If confirmed, it will also be important to conduct future research to understand
the mechanisms that underlie different QoL trajectories.
There are several other caveats that should be considered in evaluating our results. The
average QoL scores in these two studies may not be representative of all older breast cancer
patients receiving chemotherapy since research volunteers tend to be healthier than
average.25,26 However, this should not affect the internal validity of the QoL comparisons.
The two studies had different rates of lost to follow-up, with higher rates in the
observational study, although some of the women treated off-trial were not yet due for
follow-up at the time of this analysis. Higher retention in the RCT may reflect the greater
involvement of women in the RCT vs. the observational study, since one was a treatment
study and the other was not. However, there were no systematic differences in correlates of
follow-up losses between the studies (not shown), so comparisons of QoL are likely to be
internally valid. Finally, we did not have detailed and/or comparable treatment information
on factors like drug doses, symptom management and support, types of axillary procedures,
and only had information on hormonal therapy for the observational study and radiation for
the RCT. Thus, we cannot rule out unmeasured confounding variables of QoL outcomes due
to treatment variations. However, it is not likely that the RCT patients had lower levels of
use of radiation or hormonal therapy or less dose intensity than the observational group
explaining their better QoL outcomes.
In summary, these results are suggestive that there could be different QoL trajectories for
older women undergoing standard chemotherapy on- vs. off-trial. These results need to be
confirmed. If verified in future research and with other disease groups, it is possible that the
extra monitoring and reporting within a clinical trial might provide the infrastructure for
interventions to address symptoms and improve quality of life among the growing older
cancer population.
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Table 1
Characteristics of older breast cancer patients getting chemotherapy on- vs. off-trial.
All (n = 712) RCT (n = 182)a Off-trial Observational Study (n = 530)b p-valuec
Age at enrollment, mean (SD) 71.1 (SD 4.9) 72.0 (SD 4.6) 70.8 (SD 5.0) 0.002
Race, n (%)
  White, non-Hispanic 615 (86%) 157 (86%) 458 (86%) 0.959
  Non-white 97 (14) 25 (14) 72 (14)
Education level, n (%)
  High school grad 437 (61) 153 (84) 284 (54) <.001
  <High school grad 245 (34) 16 (9) 229 (43)
  Missing 30 (4) 13 (7) 17 (3)
Marital status, n (%)
  Married 414 (58) 95 (52) 319 (60) 0.320
  Not married 282 (40) 74 (41) 208 (39)
  Missing 16 (2) 13 (7) 3 (1)
ER status, n (%)
  Positive 239 (34) 65 (36) 174 (33) 0.497
  Negative 471 (66) 117 (64) 354 (67)
  Missing 2 (0) 0 (0) 2 (0)
Tumor size, n (%)
  <2 cm 297 (42) 67 (37) 230 (43) 0.005
  2 to <3 cm 198 (28) 42 (23) 156 (29)
  3+ cm 215 (30) 72 (40) 143 (27)
  Missing 2 (0) 1 (1) 1 (0)
Nodal status, n (%)
  Node positive 446 (63) 128 (70) 318 (60) 0.012
  Node negative 263 (37) 53 (29) 210 (40)
  Missing 3 (0) 1 (1) 2 (0)
Surgery, n (%)
  Breast conserving 381 (54) 77 (42) 304 (57) <.001
  Mastectomy 328 (46) 104 (57) 224 (42)
  Missing 3 (0) 1 (1) 2 (0)
Emotional support, mean (SD) 85.5 (17.8) 84.2 (19.3) 85.9 (17.3) 0.313
Tangible support, mean (SD) 86.8 (19.6) 83.1 (21.3) 88.0 (18.9) 0.008
# Comorbidities, n (%)
  0 51 (7) 19 (10) 32 (6) 0.0164
  1 138 (19) 40 (22) 98 (18)
  2 178 (25) 40 (22) 138 (26)
  3+ 326 (46) 70 (38) 256 (48)
  Missing 19 (3) 13 (7) 6 (1)
Type of site, n (%)
  Comprehensive cancer center 237 (33) 74 (41) 163 (31) 0.014
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All (n = 712) RCT (n = 182)a Off-trial Observational Study (n = 530)b p-valuec
Age at enrollment, mean (SD) 71.1 (SD 4.9) 72.0 (SD 4.6) 70.8 (SD 5.0) 0.002
  Community site 475 (67) 108 (59) 367 (69)
Legend: RCT: Randomized clinical trial, SD: Standard deviation, ER: Estrogen receptor.
a
There were 182 women completing intake interviews on the RCT; of these 150 completed mid-treatment interviews and are included in
subsequent analyses.
b
There were 647 women registered to the observational study who received chemotherapy; 530 of these women completed intake interviews.
Intake is at mid-treatment for the observational study.
c
P-values from Student’s t-tests comparing means, chi-square tests comparing categorical counts, and Cochran–Armitage trend test for comparing
the number of comorbidities between groups.
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Table 2
Unadjusted and adjusted a means of quality of life scores from mid-treatment to 24 months.
Measure
RCT (n = 150) Observational study (n = 530)
Unadjusted Adjusted Unadjusted Adjusted
Mean (95% CI) Mean (95% CI)
Global health status/QoL
  Mid-treatment 64.0 (60.4, 67.6) 64.3 (61.0, 67.6) 73.7 (72.0, 75.4) 74.1 (72.4, 75.8)
  12 months 79.2 (76.5, 81.8) 79.5 (76.1, 82.9) 81.8 (79.5, 84.1) 81.1 (78.6, 83.6)
  24 months 77.2 (74.3, 80.1) 77.9 (74.5, 81.3) 82.3 (79.4, 85.3) 81.0 (77.7, 84.4)
Physical functioning
  Mid-treatment 77.0 (73.9, 80.1) 77.4 (74.0, 80.8) 80.2 (78.2, 82.3) 81.7 (79.9, 83.5)
  12 months 82.1 (79.2, 85.1) 82.5 (79.0, 85.9) 81.6 (79.3, 83.8) 81.6 (79.6, 83.7)
  24 months 80.2 (77.1, 83.4) 80.7 (77.2, 84.3) 80.7 (78.2, 83.1) 79.8 (77.5, 82.0)
Emotional functioning
  Mid-treatment 80.7 (77.5, 83.9) 80.7 (78.1, 83.4) 91.3 (90.1, 92.5) 91.4 (89.9, 92.8)
  12 months 84.8 (82.0, 87.6) 85.2 (82.5, 87.9) 90.7 (89.3, 92.1) 90.1 (88.5, 91.7)
  24 months 84.7 (81.7, 87.7) 85.6 (82.8, 88.3) 88.8 (86.9, 90.7) 87.9 (86.2, 89.7)
Cognitive functioning
  Mid-treatment 83.8 (80.7, 86.9) 84.9 (82.1, 87.6) 90.8 (89.5, 92.1) 91.2 (89.8, 92.6)
  12 months 85.2 (83.0, 87.5) 86.4 (83.6, 89.1) 90.3 (88.8, 91.8) 90.0 (88.4, 91.6)
  24 months 84.7 (82.2, 87.2) 85.8 (83.1, 88.6) 89.3 (87.6, 91.0) 89.1 (87.4, 90.9)
Fatigue
  Mid-treatment 43.2 (39.2, 47.2) 43.8 (40.1, 47.5) 28.9 (26.8, 31.0) 28.5 (26.6, 30.4)
  12 months 25.5 (22.6, 28.4) 25.4 (21.7, 29.2) 16.9 (15.1, 18.8) 16.7 (14.6, 18.9)
  24 months 24.6 (21.6, 27.6) 24.5 (20.8, 28.3) 17.9 (15.6, 20.2) 17.4 (15.0, 19.8)
Social functioning
  Mid-treatment 75.3 (71.0, 79.6) 74.7 (71.3, 78.0) 86.8 (84.9, 88.7) 86.5 (84.7, 88.2)
  12 months 91.4 (88.5, 94.3) 91.1 (87.7, 94.6) 95.3 (94.0, 96.6) 95.7 (93.7, 97.7)
  24 months 91.2 (88.1, 94.3) 91.3 (87.8, 94.7) 95.1 (93.5, 96.8) 94.9 (92.7, 97.1)
Sexual functioning
  Mid-treatment 90.8 (87.6, 94.0) 90.8 (87.4, 94.3) 91.9 (90.4, 93.3) 92.6 (90.8, 94.3)
  12 months 87.1 (83.3, 90.9) 87.1 (83.7, 90.6) 90.1 (88.4, 91.8) 89.9 (88.0, 91.9)
  24 months 87.8 (84.0, 91.5) 87.4 (84.0, 90.9) 87.9 (85.8, 90.1) 87.6 (85.5, 89.7)
Body image
  Mid-treatment 78.6 (75.0, 82.2) 79.0 (75.8, 82.1) 90.0 (88.4, 91.5) 89.6 (87.9, 91.2)
  12 months 87.2 (84.4, 89.9) 87.8 (84.6, 91.0) 91.3 (89.6, 92.9) 91.0 (89.2, 92.8)
  24 months 87.5 (84.6, 90.4) 88.3 (85.1, 91.5) 90.6 (88.7, 92.4) 90.0 (88.1, 92.0)
Systemic therapy
side effects
  Mid-treatment 33.5 (31.0, 36.0) 34.3 (32.1, 36.6) 17.9 (16.5, 19.3) 17.5 (16.3,18.7)
  12 months 13.9 (11.8, 15.9) 14.4 (12.1, 16.8) 8.6 (7.7, 9.5) 8.7 (7.3, 10.1)
  24 months 13.2 (11.1, 15.2) 13.2 (10.8, 15.6) 9.7 (8.5, 10.9) 9.5 (8.0, 11.1)
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Legend: RCT: Randomized clinical trial, QoL: Quality of life, CI: Confidence interval.
a
Adjusted for age, education, tumor size, nodes, surgery, comorbidity, tangible support, and site type; adjusted for baseline pre-treatment physical,
emotional, social function and fatigue. We did not have comparable data on hormonal or radiation therapy or types of axillary procedures, baseline
body image, sexual or cognitive function across the studies so these are not included in the analysis.
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Table 3
Adjusted mean changes from mid-treatment to 24 months for quality of life scores among older women








Global health status/QoL 13.7 (10.2, 17.1) 7.0 (3.5, 10.4) 6.7 (1.8, 11.6) 0.007
Physical functioning 3.3 (−0.5, 7.2) −1.9 (−4.4, 0.5) 5.3 (0.7, 9.8) 0.024
Emotional functioning 4.9 (2.0, 7.8) −3.4 (−5.3,−1.6) 8.3 (4.8, 11.8) <.001
Cognitive functioning 1.0 (−2.0, 4.0) −2.1 (−4.0, −0.2) 3.1 (−0.5, 6.6) 0.090
Fatigue 19.2 (−23.7,−14.8) −11.1 (−13.8, −8.3) −8.1 (−13.4, −2.9) 0.002
Social functioning 16.6 (12.7, 20.4) 8.4 (6.0, 10.9) 8.2 (3.6, 12.7) <.001
Sexual functioning −3.4 (−6.6, −0.2) −5.0 (−6.9, −3.0) 1.6 (−2.2, 5.4) 0.405
Body image 9.3 (6.4, 12.3) 0.5 (−1.4, 2.4) 8.8 (5.3, 12.4) <.001
Systemic therapy side effects −21.1 (−23.7, −18.6) −8.0 (−9.6, −6.3) −13.2 (−16.2, −10.1) <.001
We did not have comparable data on hormonal or radiation therapy or types of axillary procedures, baseline body image, sexual or cognitive
function across the studies, so these are not included in the analysis.
Legend: RCT: Randomized clinical trial, QoL: Quality of life.
a
Linear mixed effects models, controlling for age, education, tumor size, nodal status, surgery type, number of comorbidities, tangible social
support, and site type; models for physical functioning, emotional functioning, social functioning, and fatigue outcomes included a covariate for
baseline pre-treatment level of these measures to control for potential baseline differences.
b
For global QoL, physical functioning, emotional functioning, cognitive functioning, social functioning, sexual functioning and body image, a
higher score indicates better function. For fatigue and side effects, a higher score indicates greater problems. So, a reduction in these scores
(negative sign), indicates an improvement, or decline in problems.
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